Tags: Amgen | Payout | Buyback | Plan

Amgen Boosts Payout 31%, Adds $2 Billion to Buyback Plan

Thursday, 13 Dec 2012 06:24 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Amgen Inc., the world’s largest biotechnology company, said it will increase its dividend 31 percent for the first quarter of 2013 and buy back an additional $2 billion in shares.

Amgen will pay stockholders 47 cents a share on March 7, the Thousand Oaks, California-based company said Thursday in a statement. Amgen in July 2011 became the first biotechnology company to pay a dividend. The current payment is 36 cents, and analysts estimated an increase to 40 cents, according to data compiled by Bloomberg.

Amgen is looking for new products and acquisitions to boost revenue as its former core anemia business declines. The company on Dec. 10 said it had agreed to buy DeCode Genetics Inc., a genetics research company, for $415 million. Earlier this year, Amgen acquired Micromet Inc. for $1.16 billion to add an experimental leukemia drug, signed a development deal with London-based AstraZeneca Plc and boosted its presence in the cancer market through sales of Xgeva, a bone drug that reduces fractures.

The company also said it had authorized further share repurchases with $500 million left to spend from its current $10 billion program.

© Copyright 2014 Bloomberg News. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web

Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
Privacy: We never share your email.
 

You May Also Like
Around the Web

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved